Esophageal Adenocarcinoma Clinical Trials

78 recruitingLast updated: June 17, 2026

There are 78 actively recruiting esophageal adenocarcinoma clinical trials across 35 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include New York, New York, United States, Houston, Texas, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Esophageal Adenocarcinoma Trials at a Glance

78 actively recruiting trials for esophageal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 37 trials, with the heaviest enrollment activity in New York, Houston, and Los Angeles. Lead sponsors running esophageal adenocarcinoma studies include Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Mayo Clinic, and National Cancer Institute (NCI).

Browse esophageal adenocarcinoma trials by phase

Treatments under study

About Esophageal Adenocarcinoma Clinical Trials

Looking for clinical trials for Esophageal Adenocarcinoma? There are currently 44 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 78 trials

Recruiting

Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy

Esophageal CarcinomaEsophageal AdenocarcinomaEsophagectomy+2 more
Sun Yat-sen University2,500 enrolled6 locationsNCT07309991
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled372 locationsNCT06203600
Recruiting
Phase 2

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
AstraZeneca100 enrolled70 locationsNCT07069712
Recruiting
Phase 2Phase 3

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Gastroesophageal-junction CancerEsophageal AdenocarcinomaMetastatic Gastric Cancer+1 more
Pfizer840 enrolled71 locationsNCT07392892
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 2

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Canadian Cancer Trials Group168 enrolled18 locationsNCT06043427
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled163 locationsNCT07221149
Recruiting
Phase 1Phase 2

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940
Recruiting
Not Applicable

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

Esophageal AdenocarcinomaBarrett EsophagusBarretts Esophagus With Dysplasia+1 more
Mayo Clinic450 enrolled5 locationsNCT06071845
Recruiting
Phase 1

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Colorectal, CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+1 more
Dispatch Biotherapeutics66 enrolled3 locationsNCT07544589
Recruiting
Phase 1Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 1Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled51 locationsNCT06469944
Recruiting
Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Esophageal AdenocarcinomaGastric AdenocarcinomaHER2-negative+1 more
Gilead Sciences120 enrolled1 locationNCT07546812
Recruiting
Phase 2

Obeticholic Acid for Prevention in Barrett's Esophagus

Esophageal AdenocarcinomaBarrett Esophagus
National Cancer Institute (NCI)30 enrolled8 locationsNCT04939051
Recruiting
Phase 2

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+3 more
I-Mab Biopharma US Limited180 enrolled6 locationsNCT07432295
Recruiting
Phase 1Phase 2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled45 locationsNCT06445972
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma
BeOne Medicines30 enrolled1 locationNCT07554521
Recruiting
Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled792 locationsNCT05677490
Recruiting
Phase 3

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8+10 more
NRG Oncology300 enrolled95 locationsNCT03801876